Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. All News
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about KNIGHT THERAPEUTICS INC.
12/02Knight to Present at Stifel GMP's The Future of Healthcare Conference
GL
12/02Knight to Present at Stifel GMP's The Future of Healthcare Conference
GL
11/11Knight Therapeutics Reports Q3 Basic Net Loss $0.07
MT
11/11Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 12, ..
CI
11/11Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, ..
CI
11/11Knight Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/11Knight Therapeutics Reports Third Quarter 2021
AQ
11/05Notice of Knight Therapeutics Third Quarter 2021 Results Conference Call
AQ
11/04Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call
GL
11/04Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call
GL
09/23INCYTE : Signs Supply, Distribution Deal for Tafasitamab, Pemigatinib in Latin America
MT
09/23KNIGHT THERAPEUTICS : in Supply and Distribution Agreement with NASDAQ's Incyte for Tafasi..
MT
09/23KNIGHT THERAPEUTICS BRIEF : Enters into Exclusive Supply and Distribution Agreement with N..
MT
09/23INCYTE : Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with ..
AQ
09/23Knight Therapeutics Inc. Enters into Exclusive Supply and Distribution Agreement with I..
CI
08/16KNIGHT THERAPEUTICS : Reports Second Quarter 2021
AQ
08/16NORTH AMERICAN MORNING BRIEFING : Weak Chinese -3-
DJ
08/13KNIGHT THERAPEUTICS : Posts Q2 EPS of C$0.23; Revenue Reaches Record C$65.8 Million
MT
08/13Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, ..
CI
08/13KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Posts Q2 EPS Basic C$0.2..
MT
08/13KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Reports Q2 Revenue C$65...
MT
08/13NORTH AMERICAN MORNING BRIEFING : Blockbuster -3-
DJ
08/06Notice of Knight Therapeutics' Second Quarter 2021 Results Conference Call
GL
07/13Knight Therapeutics Inc.'s Equity Buyback announced on July 10, 2020, has expired with ..
CI
07/12UPDATE : Knight Therapeutics Up 3% as Launches Normal Course Issuer Bid
MT
07/12KNIGHT THERAPEUTICS : Launches Normal Course Issuer Bid
MT
07/12Knight Therapeutics Inc. announces an Equity Buyback for 10,267,956 shares, representin..
CI
07/12KNIGHT THERAPEUTICS : Announces Normal Course Issuer Bid
AQ
07/12Knight Therapeutics Inc. authorizes a Buyback Plan.
CI
07/06Knight Therapeutics Gets Health Canada Approval for Neratinib
DJ
07/06KNIGHT THERAPEUTICS : Says Health Canada Approves Neratinib for Treatment of HER2-Positive..
MT
07/06KNIGHT THERAPEUTICS : Announces Health Canada Approval for NERLYNX« (Neratinib) to Treat H..
AQ
07/06Knight Therapeutics Announces Health Canada Approval for NERLYNX« to Treat HER2-Positiv..
CI
05/27KNIGHT THERAPEUTICS : Announces Closing of Previously Announced Acquisition and Exclusive ..
AQ
05/26Knight Therapeutics Completes US$168 Million Acquisition of Rights to Alzheimer's Drug ..
MT
05/26Knight Therapeutics Closes Previously Announced Acquisition and Details Exclusive Licen..
MT
05/26Knight Therapeutics Announces Closing of Previously Announce Acquisition and Exclusive ..
CI
05/14KNIGHT THERAPEUTICS : Swings To Q1 Profit; Reports Q1 Revenue of $46 Million
MT
05/14Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, ..
CI
05/14Knight Therapeutics Inc. Promotes Amal Khouri to Chief Business Officer
CI
05/14KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Reports Q1 Revenue $46.0..
MT
05/14Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/13Knight Therapeutics Inc. Appoints Samira Sakhia as Chief Executive Officer, Effective S..
CI
05/13KNIGHT THERAPEUTICS : IIROC Trade Resumption - GUD
AQ
05/13KNIGHT THERAPEUTICS : Rejigs Top Brass, Promotes COO to CEO; Largest Shareholder to Become..
MT
05/13Knight Therapeutics Inc. Announces Management Changes, Effective September 1, 2021
CI
05/13KNIGHT THERAPEUTICS : IIROC Trading Halt - GUD
AQ
05/12KNIGHT THERAPEUTICS : to Present at the 2021 RBC Capital Markets Global Healthcare Confere..
AQ
05/07Notice of Knight Therapeutics' First Quarter 2021 Results Conference Call
GL
05/03KNIGHT THERAPEUTICS : Maverix Private Equity Announces Team Additions
AQ
04/26KNIGHT THERAPEUTICS : to Acquire Regional Rights to Exelon
AQ
04/23KNIGHT THERAPEUTICS : To Acquire Regional Rights to Exelon For US$180 Million in Total
MT
04/23Knight Therapeutics Inc. to Acquire Regional Rights to Exelon«
CI
04/23KNIGHT THERAPEUTICS BRIEF : To Acquire Regional Rights to Exelon
MT
04/23Knight Therapeutics to Buy Regional Rights to Exelon
DJ
03/25Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, ..
CI
03/25KNIGHT THERAPEUTICS BRIEF : Reports Q4 Basic Net Earnings 0.063 Vs Forecast EPS GAAP 0.01 ..
MT
03/25Knight Therapeutics Inc. Reports Impairment Charges for the Fourth Quarter Ended Decemb..
CI
03/25Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, ..
CI
03/25Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results
GL
03/02Knight Therapeutics Announces Canadian Commercial Launch of New Treatment for Irritable..
MT
2020KNIGHT THERAPEUTICS : Files Final Base Shelf Prospectus
MT
2020KNIGHT THERAPEUTICS INC.(TSX : GUD) dropped from S&P/TSX Composite Index
CI
2020KNIGHT THERAPEUTICS INC.(TSX : GUD) dropped from S&P/TSX Capped Composite Index
CI
2020KNIGHT THERAPEUTICS INC.(TSX : GUD) dropped from S&P/TSX Completion Index
CI
2020GFL ENVIRONMENTAL AND KNIGHT THERAPE : GFL Will Be Added To, Knight Deleted From S&P/TSX C..
MT
2020KNIGHT THERAPEUTICS : S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Ind..
AQ
2020Knight Therapeutics to Seek Acquisition Opportunities
CI
2020Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, ..
CI
2020Knight Therapeutics Inc. Reports Earnings Results for the Third Quarter Ended September..
CI
2020KNIGHT THERAPEUTICS : Reports Third Quarter 2020 Results
AQ
2020Knight Therapeutics Reports Third Quarter 2020 Results
GL
2020KNIGHT THERAPEUTICS : Notice of Knight Therapeutics' Third Quarter 2020 Results Conference..
AQ
2020Notice of Knight Therapeutics' Third Quarter 2020 Results Conference Call
GL
2020KNIGHT THERAPEUTICS : Signs New Exclusive AmBisome« Agreement with Gilead in Brazil
AQ
1  2  3  4  5Next
Upcoming event on KNIGHT THERAPEUTICS INC.